Cargando…

Etanercept biosimilars

Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308636/ https://www.ncbi.nlm.nih.gov/pubmed/24980068 http://dx.doi.org/10.1007/s00296-014-3080-5

Ejemplares similares

Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2014)

Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists
por: Urbano, Paulo César Martins, et al.
Publicado: (2014)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

The biosimilars journey: current status and ongoing challenges
por: Kos, Igor Age, et al.
Publicado: (2018)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market
por: Scheinberg, Morton Aaron, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2016)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2019)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view
por: Pineda, Carlos, et al.
Publicado: (2015)

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2018)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
por: Hassett, Brian, et al.
Publicado: (2018)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali(®)) Versus Etanercept (Enbrel(®)) - Findings from a Nurse Survey in Europe
por: Thakur, Kunal, et al.
Publicado: (2016)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)

One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology
por: Müskens, Wieland D, et al.
Publicado: (2020)

Structural and In Vitro Functional Comparability Analysis of Altebrel™, a Proposed Etanercept Biosimilar: Focus on Primary Sequence and Glycosylation
por: Fazel, Ramin, et al.
Publicado: (2019)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
por: Jaworski, Janusz, et al.
Publicado: (2019)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
por: Larid, Guillaume, et al.
Publicado: (2022)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
por: Hu, Rui, et al.
Publicado: (2023)

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
por: Parisi, Simone, et al.
Publicado: (2022)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
por: Li, Kun-Peng, et al.
Publicado: (2018)

Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial
por: Zhao, Dongbao, et al.
Publicado: (2021)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eqq7rqk5uejkb4lqobnas2dh0m